Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.
Stocks · News reference
Why Is Silence Therapeutics Stock Skyrocketing Monday?
Silence Therapeutics (SLN) leaps 126% on a $1.3B cash acquisition by Merck KGaA at $20 per ADS. Deal expected to close Q1 2027.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC, in combination with cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Both companies will supply cetuximab at no cost for their respective trial sites.
Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity
The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.
Magnetic Beads Market - Global Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion
The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.
Halper Sadeh LLC Investigates Silence Therapeutics plc Acquisition
Investor rights law firm Halper Sadeh LLC is investigating whether the proposed acquisition of Silence Therapeutics plc by Merck KGaA provides fair value to shareholders.
HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.